Christopher Hagenstad
- Oncology top 5%
- Pulmonary and Respiratory Medicine top 10%
- Hepatology top 5%
- Molecular Biology
- Pathology and Forensic Medicine top 10%
- Co-authors
- Seta ShahinJohn L. MarshallDavid McCollumAllen Lee CohnEdith P. MitchellPhilip J. StellaTarek ChidiacRafael G. Amado
- Topics
- Cancer Treatment and Pharmacology (11 papers)Colorectal Cancer Treatments and Studies (5 papers)HER2/EGFR in Cancer Research (4 papers)
- Partner nations
- United StatesGermanyHungary
In The Last Decade
Christopher Hagenstad
14 papers receiving 823 citations
Hit Papers
Peers
Comparison fields: 5 of 62
- Oncology 687
- Pulmonary and Respiratory Medicine 297
- Hepatology 198
- Molecular Biology 168
- Pathology and Forensic Medicine 149
Countries citing papers authored by Christopher Hagenstad
This map shows the geographic impact of Christopher Hagenstad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Hagenstad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Hagenstad more than expected).
Fields of papers citing papers by Christopher Hagenstad
This network shows the impact of papers produced by Christopher Hagenstad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Hagenstad. The network helps show where Christopher Hagenstad may publish in the future.
Co-authorship network of co-authors of Christopher Hagenstad
This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Hagenstad. A scholar is included among the top collaborators of Christopher Hagenstad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Hagenstad. Christopher Hagenstad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 3 | |
| 3 | 3 | |
| 4 | 4 | |
| 5 | 81 | |
| 6 | 3 | |
| 7 | 7 | |
| 8 | 7 | |
| 9 | 37 | |
| 10 | 8 | |
| 11 | A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancerbreakdown → | 644 |
| 12 | 1 | |
| 13 | 13 | |
| 14 | 32 |
About Christopher Hagenstad
Christopher Hagenstad is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 14 papers that have together received 847 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (11 papers), Colorectal Cancer Treatments and Studies (5 papers) and HER2/EGFR in Cancer Research (4 papers). The work is most often cited by research in Oncology (687 citations), Hepatology (198 citations) and Pulmonary and Respiratory Medicine (297 citations). Christopher Hagenstad has collaborated with scholars based in United States, Germany and Hungary. Frequent co-authors include Seta Shahin, John L. Marshall, David McCollum, Allen Lee Cohn, Edith P. Mitchell, Philip J. Stella, Tarek Chidiac, Rafael G. Amado, J. Randolph Hecht and David R. Spigel. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.